Frantz Viral Therapeutics, LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
Phase 2
Recruiting
- Conditions
- Anal High-grade Squamous Intraepithelial LesionAnal HSILAnal HPV InfectionAIN
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Frantz Viral Therapeutics, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT06206564
- Locations
- ๐บ๐ธ
Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States
๐บ๐ธLaser Surgery Care, New York, New York, United States
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
Phase 2
Recruiting
- Conditions
- HPV InfectionVIN 3 of Usual TypeVIN Grade 2VIN Grade 3High Grade Intraepithelial NeoplasiaVulvar DiseasesVulvar HSILVIN 2 of Usual TypeVin IIVin III
- Interventions
- Drug: Placebo ointment
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Frantz Viral Therapeutics, LLC
- Target Recruit Count
- 27
- Registration Number
- NCT06075264
- Locations
- ๐บ๐ธ
Florida Gynecologic Oncology, Fort Myers, Florida, United States
๐บ๐ธAscension St. Vincent, Indianapolis, Indiana, United States
๐บ๐ธCleveland Clinic Fairview Hospital, Cleveland, Ohio, United States
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
Phase 2
Active, not recruiting
- Conditions
- Anal DysplasiaAnal High Grade Squamous Intraepithelial LesionHPV InfectionAnal Precancerous ConditionHPV DiseaseAIN 2/3
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Frantz Viral Therapeutics, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT05555862
- Locations
- ๐บ๐ธ
Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States
๐บ๐ธLaser Surgery Care, New York, New York, United States
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Phase 2
Recruiting
- Conditions
- Cervical DysplasiaHPV Related DiseaseHPV InfectionPre-Cancerous DysplasiaCIN 2/3
- Interventions
- Drug: Placebo vaginal insert
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Frantz Viral Therapeutics, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT04098744
- Locations
- ๐บ๐ธ
Florida Gynecologic Oncology, Fort Myers, Florida, United States
๐บ๐ธUniversity of Michigan, Ann Arbor, Michigan, United States
๐บ๐ธCleveland Clinic Fairview Hospital, Cleveland, Ohio, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath